Alternatives to heparin and protamine anticoagulation for cardiopulmonary bypass in cardiac surgery;Les différentes alternatives d’anticoagulation au couple héparine/protamine en chirurgie cardiaque sous circulation extra-corporelle

Canadian Journal of Anesthesia

Volumn 62, Issue 5, 2015, Pages 518-528

  Bouraghda, Aurore ^a,c   Gillois, Pierre ^b   Albaladejo, Pierre ^b  

^a UNIV GRENOBLE ALPES   (France)

^b LABORATOIRE TIMC IMAG   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; PROTAMINE; RECOMBINANT PROTEIN;

CARDIOPULMONARY BYPASS; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HUMAN; PROCEDURES;

ANTICOAGULANTS; CARDIOPULMONARY BYPASS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PROTAMINES; RECOMBINANT PROTEINS;

EID: 84939948378     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-015-0339-6     Document Type: Article

References (28)

1. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007; 21: 113-26.
2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 2121-31.
3. Park KW. Protamine and protamine reactions. Int J Anesthesiol Clin 2004; 42: 135-45.
4. Kimmel SE, Sekeres M, Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 2002; 94: 1402-8.
5. Montpas N, Desormeaux A, Keire D, Adam A. Les réactions anaphylactoïdes associées à l’héparine d’origine chinoise. Ann Pharm Fr 2011; 69: 258-64.
6. Le Meur N. Alerte Produit. Lettre d’information à l’attention des pharmaciens hospitaliers. 2013; Disponible à l’adresse URL: http://sofia.medicalistes.org/spip/IMG/pdf/Lettre_du_laboratoire_sanofi-aventis_France_aux_professionnels_de_sante_concernes.pdf (consulté janvier 2015).
7. Higgins J, Churchill R, Cumpston M, Chandler J S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011. Disponible à l’adresse URL: http://www.cochrane.org/handbook (consulté janvier 2015).
8. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131: 533-9.
9. Doherty DC, Ortel TL, de Bruijn N, Greenberg CS, Van Trigt P 3rd. “Heparin-free” cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990; 73: 562-5.
10. Grocott HP, Root J, Berkowitz SD, deBruijn N, Landolfo K. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. J Cardiothorac Vasc Anesth 1997; 11: 875-7.
11. Gillis S, Merin G, Zahger D, et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol 1997; 98: 657-9.
12. Magnani HN, Beijering RJ, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre RE, editor. New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA: Hanley & Belfus; 1997. p. 487-500.
13. Grubb KJ, Salehi P, Chedrawy EG. Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. Recent Pat Cardiovasc Drug Discov 2010; 5: 20-4.
14. Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 1990; 20: 112-8.
15. Parissis H. Lepirudin as an alternative to “heparin allergy” during cardiopulmonary bypass. J Cardiothorac Surg 2011; 6: 44.
16. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108: 2062-5.
17. Azuma K, Maruyama K, Imanishi H, Nakagawa H, Kitamura A, Hayashida M. Difficult management of anticoagulation with argatroban in a patient undergoing on-pump cardiac surgery. J Cardiothorac Vasc Anesth 2010; 24: 831-3.
18. Follis F, Filippone G, Montalbano G, et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg 2010; 10: 592-6.
19. Agarwal S, Ullom B, Al-Baghdadi Y, Okumura M. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol 2012; 28: 106-10.
20. Anand SX, Viles-Gonzalez JF, Mahboobi SK, Heerdt PM. Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition. Can J Anesth 2011; 58: 296-311.
21. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-9.
22. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83: 572-7.
23. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
24. Centre hospitalier universitaire Vaudois (CHUV). Commission permanente des médicaments. Bulletin d’information CPM No 4, 2007. Utilisation de la bivalirudine (Angiox) au CHUV. Disponible à l’adresse URL: http://www.chuv.ch/pha/pha_home/pha-medicament/pha-medicament-prescription/pha-medicament-prescription-recommandations.htm (consulté janvier 2015).
25. Ah OY, Laub GW, Southgate TJ, McGrath LB. Heparinless cardiopulmonary bypass with ancrod. Ann Thorac Surg 1994; 57: 1656-8.
26. Zulys VJ, Teasdale SJ, Michel ER, et al. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology 1989; 71: 870-7.
27. Petitou M, Nancy-Portebois V, Dubreucq G, et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009; 102: 804-10.
28. Gueret P, Krezel C, van Giersbergen PL, Fuseau E, Petitou M, Neuhart E. First human study with EP217609, a new synthetic parenteral neutralizable dual action anticoagulant. ICT 2010: 177 (résumé).